Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus

Roberto Fogari, Giuseppe Derosa, Annalisa Zoppi, Andrea Rinaldi, Paola Preti, Pierangelo Lazzari, Amedeo Mugellini

Research output: Contribution to journalArticle

Abstract

The purpose of this study was to compare the combination treatments of manidipine/delapril and olmesartan/hydrochlorothiazide (HCTZ) in elderly diabetic hypertensives. After a 4-week placebo period, 158 hypertensive patients with type 2 diabetes (age range: 66 to 74 years) were randomized to receive combination treatment of 10 mg manidipine plus 30 mg delapril or 20 mg olmesartan plus 12.5 mg HCTZ for 48 weeks in a prospective, parallel arm trial. After 12 weeks, manidipine or HCTZ was doubled in nonresponders (systolic blood pressure [SBP] ≥130 mmHg and/ or diastolic blood pressure [DBP] ≥:80 mmHg). Patients were checked at the end of the placebo period and every 12 weeks thereafter. At each visit, lying, sitting and standing BP as well as fasting glycernia, glycosylated hemoglobin (HbA1c), electrolytes, uric acid, total cholesterol (TC), hlgh-densfty lipoprotein-cholesterol (HDL-C) and triglycerides (TG) were evaluated. Both combinations reduced sitting SBP (-27.7 and -28.3 mmHg, respectively; both p

Original languageEnglish
Pages (from-to)43-50
Number of pages8
JournalHypertension Research
Volume31
Issue number1
DOIs
Publication statusPublished - Jan 2008

Keywords

  • Delapril
  • Diabetic hypertensives
  • Hydrochlorothiazide
  • Manidipine
  • Olmesartan

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus'. Together they form a unique fingerprint.

  • Cite this